• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Sun Pharma > July 30, 2010

      Robust ANDA pipeline to help Sun Pharma sustain US growth

      Posted AtEconomictimes.Indiatimes.com

      Sun Pharma’s first quarter results reflect the way the fortunes of generic Indian pharma companies swing from quarter to quarter due to one-time income earned from exclusive launch of generic drugs in the US.

      The most valuable Indian pharma company has posted better-than expected results aided by the non-recurring income earned due to distribution of generic drug Oxaliplatin by its US subsidiary Caraco. The consolidated earnings grew by nearly three-and-a-half times y-o-y while revenues increased by 78% — making it an exceptional quarter for the company.

      The operating profit margin sprang from 16% in the same quarter in the previous year to 44% this quarter. While such performance may not be repeated in the coming quarters, it has definitely helped the company to come closer to achieving its revenue growth guidance of 18-20% for FY11. The market gave a positive response to the results with the stock closing over 2% on Wednesday over its previous close.

      The company, holding 3.7% share in the domestic market, has logged a good performance in the Indian market during the quarter. Sales from domestic market contributed little less than half of the company’s total quarterly revenues and showed the maximum growth of 91%, which was understated by Rs 200 crore in the previous corresponding quarter due to change in distribution policy.

      Sun Pharma’s international formulations sales have grown by 32% y-o-y. While the non-recurring income has boosted the quarterly performance of Caraco, its manufacturing still remains suspended. A work plan submitted by the company had been approved by the US FDA in March and it expects to resolve this issue by second half of this fiscal.

      Sun Pharma has built a robust ANDA pipeline that could help it sustain its US growth. The cumulative ANDA filings with the US FDA by Sun Pharma and Caraco stand at 211, with 120 filings awaiting approval. This makes it one of the largest ANDA pipelines among its peers.

      Besides a strong ANDA pipeline, dominating position in the domestic market along with possibility of positive outcome in case of Caraco and Taro are positive factors to watch out for Sun Pharma’s investors.

      July 30, 2010


      Share this Article!

    Back to top^